CEL-SCI Corporation (NYSE MKT: CVM) announced today that the
warrants issued in connection with the public offerings in October and
December 2013 are approved for trading on the NYSE MKT and will begin
trading on February 7, 2014 under the ticker symbol “CVM WS”. CEL-SCI
issued 25,713,095 warrants to over 250 investors who participated in the
public offerings. The warrants are exercisable at $1.25 and expire on
October 11, 2018. These warrants were previously approved for trading on
the OTC Bulletin Board under the ticker symbol “CSCIW”.
CEL-SCI also received approval for electronic delivery of the warrants
from the Depository Trust Company. Investors who participated in the
public offering were sent information by mail from Computershare Trust
Company (“the Warrant Agent”) with instructions on how to trade in the
“old” warrants for “new” warrants certificates that can be deposited
with a broker electronically.
About Multikine
CEL-SCI's lead investigational therapy Multikine* (Leukocyte
Interleukin, Injection), is being developed as a potential first-line
treatment for advanced primary head and neck cancer. If it were to be
approved by regulatory agencies (e.g., FDA) for use following completion
of our clinical development program, Multikine would become an
additional and different kind of therapy in the fight against cancer:
one that aims to employ our body's immune system to fight tumors.
In October 2013, CEL-SCI announced it signed a CRADA (Cooperative
Research and Development Agreement) with the US Naval Medical Center,
San Diego to develop Multikine as a potential treatment for HIV/HPV
co-infected men and women with peri-anal warts. The Company has also
recently entered into two co-development agreements with Ergomed to
support the development of Multikine for peri-anal warts in HIV/HPV
co-infected men and women and to further develop Multikine for cervical
dysplasia/neoplasia in women who are co-infected with HIV and HPV.
About CEL-SCI
CEL-SCI is dedicated to research and development directed at improving
the treatment of cancer and other diseases by utilizing the immune
system, the body's natural defense system. The lead investigational
therapy is Multikine, currently being studied in a pivotal global Phase
III clinical trial. CEL-SCI is also investigating a different
peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for
H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid
Arthritis (currently in preclinical testing) using its LEAPS technology
platform. The investigational immunotherapy LEAPS-H1N1-DC treatment
involves non-changing regions of H1N1 Pandemic Flu (See Journal of
Clinical Investigation – J Clin Invest. 2013; 123(7):2850-2861. doi:
10.1172/JCI67550), Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI
scientists are very concerned about the possible emergence of a new more
virulent hybrid virus through the combination of H1N1 and Avian Flu, or
maybe Spanish Flu. The Company has operations in Vienna, Virginia, and
in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
* Multikine is the trademark that CEL-SCI has registered for this
investigational therapy, and this proprietary name is subject to FDA
review in connection with its future anticipated regulatory submission
for approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency. Similarly,
its safety or efficacy has not been established for any use. Moreover,
no definitive conclusions can be drawn from the early-phase,
clinical-trials data involving the investigational therapy Multikine
(Leukocyte Interleukin, Injection). Further research is required, and
early-phase clinical trial results must be confirmed in the
well-controlled, Phase III clinical trial of this investigational
therapy that is currently in progress.
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties which could cause actual results to differ
materially from those projected. Factors that could cause or contribute
to such differences include, an inability to duplicate the clinical
results demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective, receiving
necessary regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary capital
and the risk factors set forth from time to time in CEL-SCI
Corporation's SEC filings, including but not limited to its report on
Form 10-K for the year ended September 30, 2013. The Company undertakes
no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Copyright Business Wire 2014